Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

4.76 SEK

+1.06 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.06 %
-23.84 %
-5.56 %
+17.53 %
-32.00 %
-11.36 %
+16.10 %
-21.75 %
-65.60 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.02B SEK
Turnover
5.59M SEK
Revenue
46.1M
EBIT %
-714.53 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2
2026

Annual report '25

29.4
2026

Interim report Q1'26

6.5
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Press release18 hours ago

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Egetis Therapeutics
Press release12/1/2025, 10:15 AM

Members of Egetis' Leadership Team acquire shares in Egetis

Egetis Therapeutics
Press release11/27/2025, 1:07 PM

Redeye: Egetis (Q3 review) - Focus on US application

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/27/2025, 7:40 AM

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Press release11/26/2025, 2:18 PM

BioStock: Egetis strengthens regulatory path for Emcitate following positive ReTRIACt data

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q3'25
Webcast11/25/2025, 9:00 AM

Egetis Therapeutics, Audiocast, Q3'25

Egetis Therapeutics
Regulatory press release11/25/2025, 6:00 AM

Interim report Q3 2025

Egetis Therapeutics
Press release11/21/2025, 1:40 PM

Invitation to Presentation of Egetis’ Third Quarter 2025 Report on November 25, 2025

Egetis Therapeutics
Egetis Therapeutics, Audiocast, 2025
Webcast11/14/2025, 9:00 AM

Egetis Therapeutics, Audiocast, 2025

Egetis Therapeutics
Regulatory press release11/14/2025, 6:00 AM

Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency

Egetis Therapeutics
Press release11/6/2025, 10:22 AM

Egetis Therapeutics to Participate in Upcoming November Investor Conferences

Egetis Therapeutics
Regulatory press release10/31/2025, 7:00 AM

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Press Conference, 2025
Webcast10/23/2025, 8:00 AM

Egetis Therapeutics, Audiocast, Press Conference, 2025

Egetis Therapeutics
Regulatory press release10/23/2025, 6:00 AM

Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data

Egetis Therapeutics
Press release10/15/2025, 5:00 AM

Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region

Egetis Therapeutics
Press release10/10/2025, 9:18 AM

Egetis’ Nomination Committee for the 2026 Annual General Meeting

Egetis Therapeutics
Regulatory press release10/2/2025, 9:40 PM

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million

Egetis Therapeutics
Regulatory press release10/2/2025, 3:31 PM

Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares

Egetis Therapeutics
Press release8/25/2025, 9:27 AM

Redeye: Egetis Therapeutics Q2 - Great US and European progress

Egetis Therapeutics
Regulatory press release8/21/2025, 5:00 AM

Interim report Q2 2025

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.